The glioma patients were divided into nine subgroups: astrocytoma, oligodendroglioma, glioma with or without IDH mutation, glioma with IDH mutation with or without co-deletion of 1p and 19q, tumor grade II, III, and IV (Figure 3A). Here, IDH2 is linked to central nervous system cancer.